Osteoporosis: From osteoscience to neuroscience and beyond

Mechanisms of Ageing and Development

Volumn 145, Issue , 2015, Pages 26-38

  Kwan, Ping ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Bone; Homeostasis; Nerve; Neuroscience; Osteoporosis; Osteoscience

Indexed keywords

COLONY STIMULATING FACTOR 1; GLUCOCORTICOID; GROWTH FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; SEX HORMONE; TRANSCRIPTION FACTOR SOX9;

ARTICLE; BONE CHARACTERISTICS AND FUNCTIONS; BONE DENSITY; BONE TISSUE; BONE TURNOVER; CIRCULATION; GLIA; HOMEOSTASIS; HUMAN; MUSCLE; NERVE; NONHUMAN; NUTRITION; OSTEOBLASTOGENESIS; OSTEOCLASTOGENESIS; OSTEOCYTE; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PHYSICAL ACTIVITY; AGING; ANIMAL; METABOLISM; NERVOUS SYSTEM; PATHOPHYSIOLOGY;

AGING; ANIMALS; HUMANS; NERVOUS SYSTEM; OSTEOPOROSIS;

EID: 84922981705     PISSN: 00476374     EISSN: 18726216     Source Type: Journal    
DOI: 10.1016/j.mad.2015.02.001     Document Type: Review

References (116)

1. Mattingly B.E., Pillare A.C. Osteoporosis: Etiology, Diagnosis and Treatment 2009, Nova Science Pub, New York.
2. Avioli L.V. The Osteoporotic Syndrome: Detection, Prevention, Treatment 1983, Grune and Stratton.
3. Lau R.Y., Guo X. A review on current osteoporosis research: with special focus on disuse bone loss. J. Osteoporos. 2011, 10.4061/2011/293808.
4. Chenu C. Role of innervation in the control of bone remodeling. J. Musculoskel. Neuron. Interact. 2004, 4(2):132-134.
5. Clarke B.L., Khosla S. Physiology of bone loss. Radiol. Clin. North Am. 2010, 48(3):483-495.
6. Johnell O., Kanis J.A., Odén A., Sernbo I., Redlund-Johnell I., Petterson C., De Laet C., Jönsson B. Mortality after osteoporotic fractures. Osteoporos. Int. 2004, 15(1):38-42.
7. Kanis J.A. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002, 359(9321):1929-1936.
8. Kanis J.A., McCloskey E.V., Johansson H., Oden A., Melton L.J., Khaltaev N. A reference standard for the description of osteoporosis. Bone 2008, 42(3):467-475.
9. Osteoporosis in Men Osteoporosis and Related Bone Diseases 2012, NIH National Resource Center, (accessed 02.02.15.). http://www.niams.nih.gov/Health_Info/Bone/Osteoporosis/men.asp.
10. Kwan P. Sarcopenia, a neurogenic syndrome?. J. Aging Res. 2013, 10.1155/2013/791679.
11. Lee C.E., McArdle A., Griffiths R.D. The role of hormones, cytokines and heat shock proteins during age-related muscle loss. Clin. Nutr. 2007, 26(5):524-534.
12. Khosla S., Atkinson E.J., Dunstan C.R., O'Fallon W.M. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J. Clin. Endocrinol. Metab. 2002, 87(4):1550-1554.
13. Khosla S., Melton L.J., Atkinson E.J., O'Fallon W.M. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J. Clin. Endocrinol. Metab. 2001, 86(8):3555-3561.
14. Khosla S., Riggs B.L., Robb R.A., Camp J.J., Achenbach S.J., Oberg A.L., Rouleau P.A., Melton L.J. Relationship of volumetric bone density and structural parameters at different skeletal sites to sex steroid levels in women. J. Clin. Endocrinol. Metab. 2005, 90(9):5096-5103.
15. Di Girolamo D.J., Clemens T.L., Kousteni S. The skeleton as an endocrine organ. Nat. Rev. Rheumatol. 2012, 8(November (11)):674-683. (Epub 09.10.12.). 10.1038/nrrheum.2012.157.
16. Michael H., Härkönen P.L., Väänänen H.K., Hentunen T.A. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J. Bone Miner. Res. 2005, 20(12):2224-2232.
17. Huber D.M., Bendixen A.C., Pathrose P., Srivastava S., Dienger K.M., Shevde N.K., Pike J.W. Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor. Endocrinology 2001, 142(9):3800-3808.
18. 3 in human osteoblasts. Mech. Ageing Dev. 2002, 123(8):1107-1114.
19. Swerdloff R.S., Dihydrotestosterone W.C. A rationale for its use as a non-aromatizable androgen replacement therapeutic agent. Baillieres Clin. Endocrinol. Metab. 1998, 12(3):501-506.
20. Wang L., Wang Y.D., Wang W.J., Zhu Y., Li D.J. Dehydroepiandrosterone improves murine osteoblast growth and bone tissue morphometry via mitogen-activated protein kinase signaling pathway independent of either androgen receptor or estrogen receptor. J. Mol. Endocrinol. 2007, 38(4):467-479.
21. Yeh S., Miyamoto H., Shima H., Chang C. From estrogen to androgen receptor: a new pathway for sex hormones in prostate. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(10):5527-5532.
22. Gallagher J.C., Riggs B.L., DeLuca H.F. Effect of estrogen on calcium absorption and serum vitamin D metabolites in postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 1980, 51(6):1359-1364.
23. Morton D.J., Barrett-Connor E.L., Schneider D.L. Vitamin C supplement use and bone mineral density in postmenopausal women. J. Bone Miner. Res. 2001, 16(1):135-140.
24. Rhen T., Cidlowski J.A. Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N. Engl. J. Med. 2005, 353(16):1711-1723.
25. Pierce A.L., Dickey J.T., Felli L., Swanson P., Dickhoff W.W. Metabolic hormones regulate basal and growth hormone-dependent igf2 mRNA level in primary cultured coho salmon hepatocytes: effects of insulin, glucagon, dexamethasone, and triiodothyronine. J. Endocrinol. 2010, 204(3):331-339.
26. Rodan G.A. Bone homeostasis. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(November 10 (23)):13361-13362.
27. Weglein A.D. Neural Prolotherapy. J. Prolother. 2011, 3(2):639-643.
28. Serre C.M., Farlay D., Delmas P.D., Chenu C. Evidence for a dense and intimate innervation of the bone tissue, including glutamate-containing fibers. Bone 1999, 25(6):623-629.
29. Baldock P.A., Sainsbury A., Couzens M., Enriquez R.F., Thomas G.P., Gardiner E.M., Herzog H. Hypothalamic Y2 receptors regulate bone formation. J. Clin. Invest. 2002, 109(7):915-921.
30. Cherruau M., Morvan F.O., Schirar A., Saffar J.L. Chemical sympathectomy-induced changes in TH-, VIP-, and CGRP-immunoreactive fibers in the rat mandible periosteum: influence on bone resorption. J. Cell Physiol. 2003, 194(3):341-348.
31. Kwan P. Sarcopenia the gliogenic perspective. Mech. Ageing Dev. 2013, 9(September (9)):349-355. Epub 2013 jul 4. 10.1016/j.mad.2013.06.001.
32. Howe M.L., Barres B.A. A novel role for microglia in minimizing excitotoxicity. BMC Biol. 2012, 10:7. 10.1186/1741-7007-10-7.
33. Hanani M. Satellite glial cells in sympathetic and parasympathetic ganglia: in search of function. Brain Res Rev. 2010, 64(2):304-327.
34. Nixon J.E. Avascular necrosis of bone: a review. J. R. Soc. Med. 1983, 76(8):681-692.
35. Dallas S.L., Prideaux M., Bonewald L.F. The osteocyte an endocrine cell and more. Endocr. Rev. 2013, 34(October 5):658-690. (Epub ahead of print).
36. Moester M.J., Papapoulos S.E., Löwik C.W., van Bezooijen R.L. Sclerostin current knowledge and future perspectives. Calcif. Tissue Int. 2010, 87(August (2)):99-107. (Epub 15.05.10.). 10.1007/s00223-010-9372-1.
37. Ikeda T., Utsuyama M., Hirokawa K. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. J. Bone Miner. Res. 2001, 16(August (8)):1416-1425.
38. Di Nardo G., Gilardi G. Human aromatase: perspectives in biochemistry and biotechnology. Biotechno. Appl. Biochem. 2013, 60(January-February (1)):92-101. 10.1002/bab.1088.
39. Toda K., Shizuta Y. Molecular cloning of a cDNA showing alternative splicing of the 5'-untranslated sequence of mRNA for human aromatase P-450. Eur. J. Biochem. 1993, 213(April 1 (1)):383-389.
40. Ilies M., Di Costanzo L., North M.L., Scott J.A., Christianson D.W. 2-Aminoimidazole amino acids as inhibitors of the binuclear manganese metalloenzyme human arginase I. J. Med. Chem. 2010, 53(May 27 (10)):4266-4276. 10.1021/jm100306a.
41. Gacheru S.N., Trackman P.C., Shah M.A., O'Gara C.Y., Spacciapoli P., Greenaway F.T., Kagan H.M. Structural and catalytic properties of copper in lysyl oxidase. J. Biol. Chem. 1990, 265(November 5 (31)):19022-19027.
42. Peppin G.J., Weiss S.J. Activation of the endogenous metalloproteinase, gelatinase, by triggered human neutrophils. Proc. Natl. Acad. Sci. U. S. A. 1986, 83(June (12)):4322-4326.
43. Bland R. Steroid hormone receptor expression and action in bone. Clin. Sci. (London) 2000, 98(February (2)):217-240.
44. Pederson L., Kremer M., Judd J., Pascoe D., Spelsberg T.C., Riggs B.L., Oursler M.J. Androgens regulate bone resorption activity of isolated osteoclasts in vitro. Proc. Natl. Acad. Sci. U. S. A. 1999, 96(January 19 (2)):505-510.
45. Oursler M.J., Pederson L., Fitzpatrick L., Riggs B.L., Spelsberg T. Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells. Proc. Natl. Acad. Sci. U. S. A. 1994, 91(June 7 (12)):5227-5231.
46. Zhu B.T., Han G.Z., Shim J.Y., Wen Y., Jiang X.R. Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: Insights into the structural determinants favoring a differential subtype binding. Endocrinology 2006, 147(September (9)):4132-4150. (Epub 25.05.06.).
47. Kwan P., Tse T.M. mTOR and its physiological impacts-part I. An overview. J. Biochem. Pharmacol. Res. 2013, 1(2):124-137.
48. Wang Y.D., Tao M.F., Wang L., Cheng W.W., Wan X.P. Selective regulation of osteoblastic OPG and RANKL by dehydroepiandrosterone through activation of the estrogen receptor β-mediated MAPK signaling pathway. Hormone Metab. Res. 2012, 44(June (7)):494-500. (Epub 03.05.12.). 10.1055/s-0032-1311567.
49. Carroll S.H., Ravid K. Differentiation of mesenchymal stem cells to osteoblasts and chondrocytes: a focus on adenosine receptors. Expert Rev. Mol. Med. 2013, 15:e1(February 14). 10.1017/erm.2013.2.
50. Fujita T., Azuma Y., Fukuyama R., Hattori Y., Yoshida C., Koida M., Ogita K., Komori T. RUNX2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling. J. Cell Biol. 2004, 166(July 5 (1)):85-95. (Epub 28.06.04.).
51. Golub E.E., Boesze-Battaglia K. The role of alkaline phosphatase in mineralization. Curr. Opin. Orthop. 2007, 18:444-448.
52. Ducy P., Zhang R., Geoffroy V., Ridall A.L., Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997, 89(May 30 (5)):747-754.
53. Ulici V., Hoenselaar K.D., Gillespie J.R., Beier F. The PI3K pathway regulates endochondral bone growth through control of hypertrophic chondrocyte differentiation. BMC Dev. Biol. 2008, 8(April 11 (40)). 10.1186/1471-213X-8-40.
54. Liu W., Toyosawa S., Furuichi T., Kanatani N., Yoshida C., Liu Y., Himeno M., Narai S., Yamaguchi A., Komori T. Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J. Cell Biol. 2001, 155(October 1 (1)):157-166.
55. Boyce B.F., Rosenberg E., de Papp A.E., Duong le T. The osteoclast, bone remodelling and treatment of metabolic bone disease. Eur. J. Clin. Invest. 2012, 42(December (12)):1332-1341. (Epub 23.09.12.). 10.1111/j.1365-2362.2012.02717.x.
56. Kwan T.S., Amiable N., Pelletier J.P., Boileau C., Lajeunesse D., Duval N., Martel-Pelletier J. Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis. Rheumatology (Oxford) 2009, 48(December (12)):1482-1490. (Epub 17.09.09.). 10.1093/rheumatology/kep300.
57. Usui M., Xing L., Drissi H., Zuscik M., O'Keefe R., Chen D., Boyce B.F. Murine and chicken chondrocytes regulate osteoclastogenesis by producing RANKL in response to BMP2. J. Bone Miner. Res. 2008, 23(March (3)):314-325.
58. Qian Y., Zhang X.L., Zeng B.F., Jiang Y., Shen H., Wang Q. Substance P enhanced titanium particles-induced RANKL expression in fibroblasts from periprosthetic membrane. Connect. Tissue Res. 2013, 54(6):361-366. Epub 2013 Aug 23.
59. Matayoshi T., Goto T., Fukuhara E., Takano H., Kobayashi S., Takahashi T. Neuropeptide substance P stimulates the formation of osteoclasts via synovial fibroblastic cells. Biochem. Biophys. Res. Commun. 2005, 327(February 18 (3)):756-764.
60. Kawai T., Matsuyama T., Hosokawa Y., Makihira S., Seki M., Karimbux N.Y., Goncalves R.B., Valverde P., Dibart S., Li Y.P., Miranda L.A., Ernst C.W., Izumi Y., Taubman M.A. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am. J. Pathol. 2006, 169(September (3)):987-998.
61. Goto H., Hozumi A., Osaki M., Fukushima T., Sakamoto K., Yonekura A., Tomita M., Furukawa K., Shindo H., Baba H. Primary human bone marrow adipocytes support TNF-α-induced osteoclast differentiation and function through RANKL expression. Cytokine 2011, 56(December (3)):662-668. (Epub 01.10.11.). 10.1016/j.cyto.2011.09.005.
62. An J.J., Han D.H., Kim D.M., Kim S.H., Rhee Y., Lee E.J., Lim S.K. Expression and regulation of osteoprotegerin in adipose tissue. Yonsei Med. J. 2007, 48(October 31 (5)):765-772.
63. Jin J., Wang L., Wang X.K., Lai P.L., Huang M.J., Jin D.D., Zhong Z.M., Chen J.T., Bai X.C. Risedronate inhibits bone marrow mesenchymal stem cell adipogenesis and switches RANKL/OPG ratio to impair osteoclast differentiation. J. Surg. Res. 2013, 180(March (1)):e21-e29. (Epub 31.03.12.). 10.1016/j.jss.2012.03.018.
64. Eghbali-Fatourechi G., Khosla S., Sanyal A., Boyle W.J., Lacey D.L., Riggs B.L. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J. Clin. Invest. 2003, 111(April (8)):1221-1230.
65. Kulkarni R.N., Bakker A.D., Everts V., Klein-Nulend J. Mechanical loading prevents the stimulating effect of IL-1β on osteocyte-modulated osteoclastogenesis. Biochem. Biophys. Res. Commun. 2012, 420(March 30 (1)):11-16. (Epub 27.02.12.). 10.1016/j.bbrc.2012.02.099.
66. Wei S., Kitaura H., Zhou P., Ross F.P., Teitelbaum S.L. IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Invest. 2005, 115(February (2)):282-290.
67. Reddi D., Bostanci N., Hashim A., Aduse-Opoku J., Curtis M.A., Hughes F.J., Belibasakis G.N. Porphyromonas gingivalis regulates the RANKL-OPG system in bone marrow stromal cells. Microb. Infect. 2008, 10(November-December (14-15)):1459-1468. (Epub 26.08.08.). 10.1016/j.micinf.2008.08.007.
68. Hofbauer L.C., Lacey D.L., Dunstan C.R., Spelsberg T.C., Riggs B.L., Khosla S. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999, 25(September (3)):255-259.
69. 4+ T lymphocytes synthesize and release functional osteoprotegerin in vitro. Lab. Invest. 2008, 88(February (2)):171-184. (Epub 26.11.07.).
70. Li Y., Toraldo G., Li A., Yang X., Zhang H., Qian W.P., Weitzmann M.N. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 2007, 109(May 1 (9)):3839-3848. (Epub 03.01.07.).
71. Crotti T., Smith M.D., Hirsch R., Soukoulis S., Weedon H., Capone M., Ahern M.J., Haynes D. Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J. Periodont. Res. 2003, 38(August (4)):380-387.
72. Arai F., Miyamoto T., Ohneda O., Inada T., Sudo T., Brasel K., Miyata T., Anderson D.M., Suda T. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J. Exp. Med. 1999, 190(December 20 (12)):1741-1754.
73. Lekesiz K., Naumnik B., Borysewicz-Sanczyk H., Koc-Zurawska E., Mysliwiec M. Effect of unfractionated heparin, enoxaparin and sulodexide on the relations between secretion and expression of OPG, RANKL and vWF in HUVEC. Folia Histochem. Cytobiol. 2013, 51(2):156-163. 10.5603/FHC.2013.0016.
74. Hanada R., Hanada T., Sigl V., Schramek D., Penninger J.M. RANKL/RANK - beyond bones. J. Mol. Med. (Berlin) 2011, 89(July (7)):647-656. (Epub 29.03.11.). 10.1007/s00109-011-0749-z.
75. Kanamaru F., Iwai H., Ikeda T., Nakajima A., Ishikawa I., Azuma M. Expression of membrane-bound and soluble receptor activator of NF-kappaB ligand (RANKL) in human T cells. Immunol. Lett. 2004, 94(July 15 (3)):239-246.
76. Boyce B.F., Yao Z., Xing L. Osteoclasts have multiple roles in bone in addition to bone resorption. Crit. Rev. Eukaryot. Gene Expr. 2009, 19(3):171-180.
77. Takayanagi H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J. Mol. Med. (Berlin) 2005, 83(March (3)):170-179. (Epub 26.01.05.).
78. Wada T., Nakashima T., Hiroshi N., Penninger J.M. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol. Med. 2006, 12(January (1)):17-25. (Epub 13.12.05.).
79. Ha H., Kwak H.B., Lee S.W., Jin H.M., Kim H.M., Kim H.H., Lee Z.H. Reactive oxygen species mediate RANK signaling in osteoclasts. Exp. Cell Res. 2004, 301(December 10 (2)):119-127.
80. Shipman C.M., Croucher P.I. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 2003, 63(March 1 (5)):912-916.
81. Weitzmann M.N. The role of inflammatory cytokines, the RANKL/OPG axis, and the immunoskeletal interface in physiological bone turnover and osteoporosis. Scientifica 2013, 2013(125705). 10.1155/2013/125705.
82. Yao Z., Li P., Zhang Q., Schwarz E.M., Keng P., Arbini A., Boyce B.F., Xing L. Tumor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression. J. Biol. Chem. 2006, 281(April 28 (17)):11846-11855. (Epub 06.02.06.).
83. Weir E.C., Lowik C.W., Paliwal I., Insogna K.L. Colony stimulating factor-1 plays a role in osteoclast formation and function in bone resorption induced by parathyroid hormone and parathyroid hormone-related protein. J. Bone Miner. Res. 1996, 11(October (10)):1474-1481.
84. Zaidi M. Skeletal remodeling in health and disease. Nat. Med. 2007, 13(July (7)):791-801.
85. Itonaga I., Sabokbar A., Sun S.G., Kudo O., Danks L., Ferguson D., Fujikawa Y., Athanasou N.A. Transforming growth factor-beta induces osteoclast formation in the absence of RANKL. Bone 2004, 34(January (1)):57-64.
86. Hanada R., Leibbrandt A., Hanada T., Kitaoka S., Furuyashiki T., Fujihara H., Trichereau J., Paolino M., Qadri F., Plehm R., Klaere S., Komnenovic V., Mimata H., Yoshimatsu H., Takahashi N., von Haeseler A., Bader M., Kilic S.S., Ueta Y., Pifl C., Narumiya S., Penninger J.M. Central control of fever and female body temperature by RANKL/RANK. Nature 2009, 462(November 26 (7272)):505-509. 10.1038/nature08596.
87. Tyagi A.M., Srivastava K., Mansoori M.N., Trivedi R., Chattopadhyay N., Singh D. Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis. PLoS ONE 2012, 7(9):e44552. (Epub 10.09.12.). 10.1371/journal.pone.0044552.
88. Ascenzi P., Bocedi A., Marino M. Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol. Aspects Med. 2006, 27(August (4)):299-402. (Epub 17.08.06.).
89. Chen H.T., Tsou H.K., Chang C.H., Tang C.H. Hepatocyte growth factor increases osteopontin expression in human osteoblasts through PI3K, Akt c-Src and AP-1 signaling pathway. PLoS ONE 2012, 7(6):e38378. (Epub 04.06.12.). 10.1371/journal.pone.0038378.
90. Chen K., Aenlle K.K., Curtis K.M., Roos B.A., Howard G.A. Hepatocyte growth factor (HGF) and 1,25-dihydroxyvitamin D together stimulate human bone marrow-derived stem cells toward the osteogenic phenotype by HGF-induced up-regulation of VDR. Bone 2012, 51(July (1)):69-77. (Epub 12.04.12.). 10.1016/j.bone.2012.04.002.
91. Tsai S.Y., Huang Y.L., Yang W.H., Tang C.H. Hepatocyte growth factor-induced BMP-2 expression is mediated by c-Met receptor, FAK, JNK, RUNX2, and p300 pathways in human osteoblasts. Int. Immunopharmacol. 2012, 13(June (2)):156-162. (Epub 11.04.12.). 10.1016/j.intimp.2012.03.026.
92. Yoshida S., Iwasaki R., Kawana H., Miyauchi Y., Hoshi H., Miyamoto H., Mori T., Kanagawa H., Katsuyama E., Fujie A., Hao W., Kobayashi T., Sato Y., Miyamoto K., Morioka H., Matsumoto M., Chiba K., Toyama Y., Nakagawa T., Miyamoto T. PDGFBB promotes PDGFRα-positive cell migration into artificial bone in vivo. Biochem. Biophys. Res. Commun. 2012, 421(May 18 (4)):785-789. (Epub 23.04.12.). 10.1016/j.bbrc.2012.04.084.
93. Taylor R.M., Kashima T.G., Knowles H.J., Athanasou N.A. VEGF, FLT3 ligand, PlGF and HGF can substitute for M-CSF to induce human osteoclast formation: implications for giant cell tumour pathobiology. Lab. Invest. 2012, 92(October (10)):1398-1406. (Epub 20.08.12.). 10.1038/labinvest.2012.108.
94. Kristensen I.B., Christensen J.H., Lyng M.B., Møller M.B., Pedersen L., Rasmussen L.M., Ditzel H.J., Abildgaard N. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease. Br. J. Haematol. 2013, 161(May (3)):373-382. (Epub 22.02.13.). 10.1111/bjh.12270.
95. Sato M., Asada N., Kawano Y., Wakahashi K., Minagawa K., Kawano H., Sada A., Ikeda K., Matsui T., Katayama Y. Osteocytes regulate primary lymphoid organs and fat metabolism. Cell Metab. 2013, 18(November 5 (5)):749-758. (Epub 17.10.13.). 10.1016/j.cmet.2013.09.014.
96. Tortora G.J., Derrickson B.H. The skeletal system: bone tissue. Principles of Anatomy and Physiology 2012, John Wiley & Sons, USA, pp. 182-207 (Chapter 6). 13th edition.
97. Tortora G.J., Derrickson B.H. The skeletal system: the axial skeleton. Principles of Anatomy and Physiology 2012, John Wiley & Sons, USA, pp. 208-254 (Chapter 7). 13th edition.
98. Tortora G.J., Derrickson B.H. Nervous tissue. Principles of Anatomy and Physiology 2012, John Wiley & Sons, USA, pp. 447-491 (Chapter 12). 13th edition.
99. Tortora G.J., Derrickson B.H. The endocrine system. Principles of Anatomy and Physiology 2012, John Wiley & Sons, USA, pp. 680-727 (Chapter 18). 13th edition.
100. Tortora G.J., Derrickson B.H. The cardiovascular system: the blood. Principles of Anatomy and Physiology 2012, John Wiley & Sons, USA, pp. 728-756 (Chapter 19). 13th edition.
101. Marieb E.N., Wilhelm P.B., Mallatt J.B. Bones and skeletal tissues. Human Anatomy 2014, Pearson Education, USA, pp. 123-149 (Chapter 6). 7th edition.
102. Brandi M.L. Microarchitecture the key to bone quality. Rheumatology (Oxford) 2009, 48(October):3-8. (Suppl. 4:IV). 10.1093/rheumatology/kep273.
103. O'Brien C.A., Plotkin L.I., Galli C., Goellner J.J., Gortazar A.R., Allen M.R., Robling A.G., Bouxsein M., Schipani E., Turner C.H., Jilka R.L., Weinstein R.S., Manolagas S.C., Bellido T. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE 2008, 3(August 13 (8)):e2942. 10.1371/journal.pone.0002942.
104. Qing H., Ardeshirpour L., Pajevic P.D., Dusevich V., Jähn K., Kato S., Wysolmerski J., Bonewald L.F. Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation. J. Bone Miner. Res. 2012, 27(May (5)):1018-1029. 10.1002/jbmr.1567.
105. McKane W.R., Khosla S., Burritt M.F., Kao P.C., Wilson D.M., Ory S.J., Riggs B.L. Mechanism of renal calcium conservation with estrogen replacement therapy in women in early postmenopause - a clinical research center study. J. Clin. Endocrinol. Metab. 1995, 80(December (12)):3458-3464.
106. Jähn K., Lara-Castillo N., Brotto L., Mo C.L., Johnson M.L., Brotto M., Bonewald L.F. Skeletal muscle secreted factors prevent glucocorticoid-induced osteocyte apoptosis through activation of β-catenin. Eur. Cells Mater. 2012, 24(September 12):197-209. (discussion 209-10).
107. Faul C., Amaral A.P., Oskouei B., Hu M.C., Sloan A., Isakova T., Gutiérrez O.M., Aguillon-Prada R., Lincoln J., Hare J.M., Mundel P., Morales A., Scialla J., Fischer M., Soliman E.Z., Chen J., Go A.S., Rosas S.E., Nessel L., Townsend R.R., Feldman H.I., St John Sutton M., Ojo A., Gadegbeku C., Di Marco G.S., Reuter S., Kentrup D., Tiemann K., Brand M., Hill J.A., Moe O.W., Kuro-O M., Kusek J.W., Keane M.G., Wolf M. FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 2011, 121(November (11)):4393-4408. (Epub 10.10.11.). 10.1172/JCI46122.
108. Charatcharoenwitthaya N., Khosla S., Atkinson E.J., McCready L.K., Riggs B.L. Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women. J. Bone Miner. Res. 2007, 22(May (5)):724-729.
109. Shevde N.K., Bendixen A.C., Dienger K.M., Pike J.W. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc. Natl. Acad. Sci. U. S. A. 2000, 97(July 5 (14)):7829-7834.
110. Brückner K. Blood cells need glia, too: a new role for the nervous system in the bone marrow niche. Cell Stem Cell 2011, 9(December 2 (6)):493-495. 10.1016/j.stem.2011.11.016.
111. Lobstein J.G.C.F.M. Lehrbuch der Pathologischen Anatomie 1835, Bd II, Stuttgart.
112. Yamazaki S., Nakauchi H. Bone marrow Schwann cells induce hematopoietic stem cell hibernation. Int. J. Hematol. 2014, 99(June (6)):695-698. (Epub 10.05.14.). 10.1007/s12185-014-1588-9.
113. Xie H., Cui Z., Wang L., Xia Z., Hu Y., Xian L., Li C., Xie L., Crane J., Wan M., Zhen G., Bian Q., Yu B., Chang W., Qiu T., Pickarski M., Duong le T., Windle J.J., Luo X., Liao E., Cao X. PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis. Nat. Med. 2014, 20(November (11)):1270-1278. (Epub 05.10.14.). 10.1038/nm.3668.
114. Yamazaki S., Ema H., Karlsson G., Yamaguchi T., Miyoshi H., Shioda S., Taketo M.M., Karlsson S., Iwama A., Nakauchi H. Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell 2011, 147(November 23 (5)):1146-1158. 10.1016/j.cell.2011.09.053.
115. García-Castellano J.M., Díaz-Herrera P., Morcuende J.A. Is bone a target-tissue for the nervous system? New advances on the understanding of their interactions. Iowa Orthopaed. J. 2000, 20:49-58.
116. Colaianni G., Cuscito C., Mongelli T., Oranger A., Mori G., Brunetti G., Colucci S., Cinti S., Grano M. Irisin enhances osteoblast differentiation in vitro. Int. J. Endocrinol. 2014, 2014:902186. (Epub 04.03.14.). 10.1155/2014/902186.